Minimally invasive versus open surgery for gallbladder cancer: A systematic review and meta-analysis.

Surg OncolJul 23, 2026 (epub)
Clinical ResearchGeneral SurgeryOncology (Medical)

Abhay K Kattepur, Mufaddal Kazi, Gurudutt P Varty et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the post-operative outcomes of minimally invasive surgery (MIS) versus open surgery for gallbladder cancer in 8,568 patients. The study found that MIS was associated with lower overall morbidity (OR 0.60) and mortality (OR 0.62), although it had a higher risk of R1 resection (OR 1.34).

Key findings

  • MIS showed lower overall morbidity with an odds ratio of 0.60.
  • Mortality rates were lower in the MIS group, with an odds ratio of 0.62.
  • Patients undergoing MIS had a shorter hospital stay by an average of 3 days.
  • R1 resection rates were higher in the MIS group, with an odds ratio of 1.34.

Why it matters

Understanding the comparative outcomes of MIS and open surgery for gallbladder cancer is crucial for surgical decision-making, particularly regarding post-operative morbidity and mortality, which can significantly impact patient recovery and overall care.

What to keep in mind

The certainty of evidence was very low to low across the included studies.

Source

PubMed · PMID 42520691

Published in Surg Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.